the aid library

Medicinal products under development for the treatment of Ebola

European Medicines Agency EMA (2014)

Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines ... more

Zambia: GUIDELINES ON REGULATING THE CONDUCT OF CLINICAL TRIAL IN HUMAN PARTICIPANTS

Zambia Medicines Regulatory Authority (ZAMRA) (2016) C2

First Edition

Zambia: GENERAL GUIDELINES FOR SUBMITTING APPLICATIONS FOR REGISTRATION OF A MEDICINE

Zambia Medicines Regulatory Authority (ZAMRA) (2016) C2

First Edition

Buruli Ulcer: a Review of the Current Knowledge

Yotsu,R.R.; K. Suzuki, R. E. Simmonds Current Tropical Medicines Report (2018) CC

Current Tropical Medicine Reports (2018) 5:247–256 https://doi.org/10.1007/s40475-018-0166-2 .Purpose of the Review Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aim ... more

GUIDELINES FOR GOOD CLINICAL TRIAL PRACTICE IN ZIMBABWE

Medicines Control Authority of Zimbabwe (MCAZ) (2012) C2

Seasonal Malaria Chemoprevention SMC Training Manual

Medicines for Malaria Venture MMV (2013) CC

This comprehensive reference document is intended for those responsible for training in SMC (Seasonal Malaria Chemoprevention). It assumes that SMC will be implemented using the Community Health Worker strategy.

Background Paper 6.11 Alzheimer Disease and other Dementias

B. Duthey, Ph.D; S. Tanna (2004) C2

20 February 2013 Update on 2004 Background Paper (Written by Saloni Tanna) Priority Medicines for Europe and the World "A Public Health Approach to Innovation"

Antimicrobial Resistance Surveillance Guidance for the African Region

Africa Center for Disease Control and Prevention (2024) CC

Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and ... more

Falling short

International Union Against Tuberculosis and Lung Disease; Treatment Action Group; msh; ec al. (2017)

Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis. Accessed in November 2017.

WHO response to the Ukraine crisis: February 2023 bulletin

World Health Organization (WHO) (2022) C_WHO

This bulletin focuses on the situation in Ukraine and several key refugee-receiving countries (‎Bulgaria, Czechia, Hungary, Poland, Republic of Moldova, Romania, and Slovakia)‎, with the understanding that other countries in the European Region ... more

Pathways of antibiotic use in Bangladesh: qualitative protocol for the PAUSE study

Rousham E. K., M. Aminul Islam, P. Nahar et al. (2018) C2

Global actions to reduce antimicrobial resistance (AMR) include optimising the use of antimicrobial medicines in human and animal health. In countries with weak healthcare regulation, this requires a greater understanding of the drivers of antibioti ... more

Cardiovascular diseases in Africa in the twenty-first century: Gaps and priorities going forward

Minja, N.W.; Nakagaayi, D.; Aliku, T. et al. Frontiers in Cardiovascular Medicine (2022) CC

In 2015, the United Nations set important targets to reduce premature cardiovascular disease (CVD) deaths by 33% by 2030. Africa disproportionately bears the brunt of CVD burden and has one of the highest risks of dying from non-communicable diseases (NCDs) worldwide. There is currently an epide ... miological transition on the continent, where NCDs is projected to outpace communicable diseases within the current decade. Unchecked increases in CVD risk factors have contributed to the growing burden of three major CVDs—hypertension, cardiomyopathies, and atherosclerotic diseasesleading to devastating rates of stroke and heart failure. The highest age standardized disability-adjusted life years (DALYs) due to hypertensive heart disease (HHD) were recorded in Africa. The contributory causes of heart failure are changing—whilst HHD and cardiomyopathies still dominate, ischemic heart disease is rapidly becoming a significant contributor, whilst rheumatic heart disease (RHD) has shown a gradual decline. In a continent where health systems are traditionally geared toward addressing communicable diseases, several gaps exist to adequately meet the growing demand imposed by CVDs. Among these, high-quality research to inform interventions, underfunded health systems with high out-of-pocket costs, limited accessibility and affordability of essential medicines, CVD preventive services, and skill shortages. Overall, the African continent progress toward a third reduction in premature mortality come 2030 is lagging behind. More can be done in the arena of effective policy implementation for risk factor reduction and CVD prevention, increasing health financing and focusing on strengthening primary health care services for prevention and treatment of CVDs, whilst ensuring availability and affordability of quality medicines. Further, investing in systematic country data collection and research outputs will improve the accuracy of the burden of disease data and inform policy adoption on interventions. This review summarizes the current CVD burden, important gaps in cardiovascular medicine in Africa, and further highlights priority areas where efforts could be intensified in the next decade with potential to improve the current rate of progress toward achieving a 33% reduction in CVD mortality. more

The Interagency Emergency Health Kit 2017
recommended

World Health Organization WHO; UNICEF; ICRC; et al. (2019) C_WHO

Interagency Guidelines; Medicines and medical devices for 10 000 people for approximately three month.

A model quality assurance system for procurement agencies

World Health Organization World Health Organization, United Nations Children's Fund, United Nations Development Programme, United Nations Populations Fund, World Bank (2007) C_WHO

This interagency report provides recommendations for assuring quality of medicines during key activities of country-level procurement agencies, namely prequalification of pharmaceutical products and manufacturers; purchase of pharmaceutical products ... more

Pharmacological treatment of mental disorders in primary health care

World Health Organization WHO (2009) CC

The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalised anxiety and sleep disorders; obsessive-compulsive disorders and panic attacks; an ... more

Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB)
recommended

World Health Organization WHO (2018) C_WHO

The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be incr ... more

United Republic of Tanzania: Hypertension Fact Sheet

World Health Organization WHO (2021) C_WHO

In 2012, 25.7% of adults in Tanzania aged 25–64 had hypertension, affecting approximately 4 million people. However, most remain unaware of their condition or are not receiving treatment, with only 0.1 million achieving blood pressure control.

Use of the WHO Access, Watch, and Reserve classification to define patterns of hospital antibiotic use (AWaRe): an analysis of paediatric survey data from 56 countries

Hsia Y., B. R Lee, A. Versporten, et al The Lancet (2019) C2

Improving the quality of hospital antibiotic use is a major goal of WHO’s global action plan to combat antimicrobial resistance. The WHO Essential Medicines List Access, Watch, and Reserve (AWaRe) classification could facilitate simple stewardship ... more